Unparalleled Psychedelic Investing Data and Analysis

Psychedelic Invest is a resource for those looking to invest in the burgeoning psychedelic industry.

Track the entire psychedelic market

Track the entire psychedelic market

We’ve developed the first all encompassing index to track the public psychedelic marketplace.

Explore the Index

Just Some of the Data we Cover

Latest News

Press

PsyBio Therapeutics Corp. Begins Trading on the TSX Venture Exchange

PsyBio Therapeutics Corp. announced that the company will commence trading on the TSX Venture Exchange under the ticker symbol “PSYB”.

Pharmadrug Press

PharmaDrug Files For FDA Orphan Drug Designation For DMT

PharmaDrug Inc. announced it has expanded its psychedelic pharmaceutical program with the filing of an application with the U.S. Food and Drug Administration.

NeonMind Press

NeonMind Purchases Synthetic Psilocybin from Psygen Labs Human Clinical Trial

NeonMind Biosciences Inc. announced that it has purchased an initial order of GMP grade psilocybin from Psygen Labs Inc.

Pharmather Press

PharmaTher Announces Research Collaboration for Novel Microneedle Delivery of Psychedelic Pharmaceuticals

PharmaTher Inc. announced that they have entered into a sponsored research agreement with the Terasaki Institute to develop a novel microneedle patch that aims to deliver psychedelic pharmaceuticals.

Press

Awakn Chief Medical Officer Announces Results of the World’s First ‘MDMA in Alcohol Use Disorder’ Trial

Awakn Life Sciences Inc. announced the publication of results from its CMO Dr. Ben Sessa’s Bristol Imperial MDMA in Alcoholism (BIMA) trial.

atai and bionomics Analysis

Atai Life Sciences Partners with Bionomics on MDMA Combination Therapies

Bionomics (BNO), an Australian listed clinical stage biopharmaceutical company announced on Wednesday that it has partnered with EmpathBio, a subsidiary of the largest private psychedelic company, ATAI Life Sciences. Through the new partnership, the companies will explore a combination drug treatment regimen using EmpathBio’s MDMA derivative, EMP-01, and Bionomics’ lead drug candidate, BNC210.  The regimen […]

Mindset Pharma Press

Mindset Pharma Added to North American Psychedelics Index

Mindset Pharma Inc. announced that it has been added to the North American Psychedelics Index.

Explore the Psychedelic Landscape

Learn more about the psychedelic companies changing the industry.